Answers are grounded in this paper and cite their sources.
Analysis reveals insufficient varieties of glucocorticosteroids in pharmacies for atopic dermatitis management in children, suggesting further development.
In the last decade, there has been a steady upward trend in the incidence of atopic dermatitis, a genetically determined inflammatory skin disease, among the child population. The inclusion of topical glucocorticosteroids in pediatric practice is justified, since these drugs control the symptoms of dermatological disease, reduce the risk of severe course of the pathological process. In the course of the work, a list of glucocorticosteroids for topical use presented in pharmacies of the metropolis was studied. An assessment of the range of drugs in this group revealed that the proposed drugs have a variety of release forms and a wide price range. A study of the ratio of imported and domestic drugs revealed that the main country producing the analyzed drugs is Russia. However, in the list of these pharmacies at the time of the study, an insufficient range of concentrations (weak, moderate or strong activity) of topical glucocorticosteroids was noted, indicated in clinical guidelines for the treatment of atopic dermatitis in children. Thus, it has been established that it is necessary to expand the range of glucocorticosteroids for topical use for pharmacotherapy of atopic dermatitis in children of different age groups.
No takes yet. Share an insight, caveat, or question.
Salnikova et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: